Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGWD for nab-Paclitaxel-Induced Neurotoxicity in Breast Cancer
NCT05566457Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of huang qi gui zhi wu wu tang in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: European Organisation for the Research and Treatment of Cancer-Chemotherapy-induced peripheral neuropathy questionnaire at 3 months. Status: unknown.
02
Drugs
huang qi gui zhi wu wu tang
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05566457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566457.